On March 13, 2014, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) reported its Q4 2013 and full-year 2013 financial results. Q4 2013 total revenues decreased by 66.6% YoY to c. $3.0 million, mainly due to prior year partnering transactions, while full-year 2013 total revenues declined by 44.0% YoY at $7.9 million. Net loss for Q4 2013 was $8.6 million or $0.14 loss per diluted share, compared to net loss of $0.3 million or $0.01 loss per diluted share in Q4 2012. Net loss for full year 2013 was $42.6 million or $0.76 per diluted share, compared to net loss of $35.4 million or $1.02 per diluted share in full year 2012. The Company also announced that it is commencing clinical development of MIP-1095, a PSMA-targeted small molecule radiopharmaceutical for treating prostate cancer. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) stock opened today at $4.02 and is currently trading at $4.26. The stock showed a positive weekly performance of -4.44%.
ROI Acquisition Corp (NASDAQ:EVRY) posted its quarterly earnings results on Monday. The company reported ($0.05) earnings per share for the quarter, missing the analysts’ consensus estimate of $0.29 by $0.34, Analyst Ratings Network.com reports. The company had revenue of $129.30 million for the quarter, compared to the consensus estimate of $137.53 million. ROI Acquisition Corp’s revenue was up 6.2% compared to the same quarter last year. ROI Acquisition Corp (NASDAQ:EVRY) stock opened at $4.00, in current trading session and currently is at $4.06, by loosing -10.96%. The 52 week range of $3.53-$13.74. Company’s market capitalization is $100.53 billion.
Jefferies analyst Biren Amin weighed in on The Medicines Company (NASDAQ:MDCO) after a Delaware district court ruled in favor of Hospira on the Angiomax patent case. Amin commented, “U.S. District Court of Delaware Judge Richard Andrews issued his ruling on the Angiomax ‘727 and ‘343 patents. Judge Andrews found HSP did not infringe both of these patents despite ruling that HSP failed to invalidate both patents on prior art/obviousness grounds. MDCO will likely appeal the ruling – which could take another 6-9 months, and even potentially settle. Under a worst-case scenario, HSP may launch in mid-’15 implying a potential $19 fair value. The Medicines Company (NASDAQ:MDCO) stock is currently trading at $24.03 .The EPS of the stock is 0.23. Company’s market capitalization is $1.55 billion.
Sangamo Biosciences (NASDAQ:SGMO) was the target of a significant increase in short interest during the month of January. As of March 14th, there was short interest totalling 11,166,388 shares, an increase of 24.8% from the February 28th total of 8,950,725 shares, Stock Ratings Network.com reports. Based on an average daily trading volume, of 2,933,706 shares, the short-interest ratio is currently 3.8 days. Approximately 18.5% of the company’s shares are short sold. Sangamo Biosciences, Inc. (NASDAQ:SGMO) stock opened the session at $17.62, and now is at $18.00. The 52 week range of the SGMO stock remained $6.86-$24.69 and the day range was $17.33-$18.08.